Hans W. Vahlteich Professor of Pharmacy
University of Michigan
Dr. Anna Schwendeman is the Hans W. Vahlteich Professor of Pharmacy and a member of the Biointerfaces Institute at the University of Michigan. She obtained her B.S. in Physical Chemistry from the Moscow Institute of Physics and Technology and her Ph.D. in Pharmaceutics from Ohio State University. In 2016, she co-founded a company EVOQ Therapeutics, focused on the use of HDL nanodiscs for delivery of personalized neoantigen cancer vaccines. Prior to starting her academic career in 2012, Dr. Schwendeman spent 12 years working in the pharmaceutical industry at Esperion Therapeutics, Pfizer, and Cerenis Therapeutics, focusing on the translation from discovery to Phase 2 clinical trials of cardiovascular nanomedicines. Her current research is focused on the development of novel HDL mimetics for the treatment of sepsis, lysosomal storage diseases, and drug and vaccine delivery applications. She is also co-Director of FDA sponsored Center for Research in Complex Generics and an Associate Editor for Nanomedicine NBM and Eur. J. Pharm and Biopharm.